Page 62 - ஹைதராபாத் அடிப்படையிலானது பாரத் பயோடெக் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

India breaks world s daily COVID-19 record with 314,835 new cases in last 24 hours

India’s total COVID-19 infection count is over 15.9 million 2,104 new deaths were announced in the same period Indian authorities reported 314,835 new COVID-19 cases today, bringing the country’s total infection count to over 15.9 million. 2,104 new deaths were announced in the same period, with fatalities reaching a cumulative 184,657 since the beginning of India’s coronavirus epidemic. India has topped the world’s record for daily COVID-19 new case tallies as the country sees a huge spike in the virus outbreak. Today’s numbers blew past the previous global one-day high of 297,430 infections, which was tallied in the US in January. The recent surge in India’s coronavirus outbreak is believed to be driven by a new indigenous variant of the pathogen, dubbed B1617, which contains two mutations that appear to make the bug more infectious.

United kingdomHyderabad based bharat biotechஒன்றுபட்டது கிஂக்டம்ஹைதராபாத் அடிப்படையிலானது பாரத் பயோடெக்

COVID-19 Vaccination Registration for All Indians Aged Above 18 Begins May 1: How to Register

COVID-19 Vaccination Registration for All Indians Aged Above 18 Begins May 1: How to Register All eligible citizens can register through the CoWIN platform and the Aarogya Setu app. By Tasneem Akolawala | Updated: 21 April 2021 13:14 IST The vaccination drive in India currently offers two vaccines – Covaxin and Covishield. Highlights Currently, vaccines are given to citizens above age 45 Each citizen has to take two shots of the vaccine The Government of India has announced phase 3 of the vaccination drive in the country amidst the steep spike in COVID-19 cases. All citizens aged above 18 will be eligible for vaccination starting May 1. Currently, only citizens above the age of 45 were allowed to take the vaccine. India s fresh cases tally at 2.94 lakhs – the second highest ever recorded globally. Users need to register for the vaccine online before heading to the hospitals and getting their first shot.

Aargya setuAarogya setuSerum institute of indiaHyderabad based bharat biotechSerum instituteCenter phoneCovid 19 vaccines 18 years registration coronavirus may 1 how to register cowinVaccination driveCovid 19Covid 19 vaccineஆரோக்கிய செத்துசீரம் நிறுவனம் ஆஃப் இந்தியாஹைதராபாத் அடிப்படையிலானது பாரத் பயோடெக்சீரம் நிறுவனம்தடுப்பூசி இயக்கி

Phase-3 Trials: Covaxin Demonstrates 100 Per Cent Efficacy Against Severe COVID-19, Overall Interim Clinical Efficacy 78 Per Cent

Phase-3 Trials: Covaxin Demonstrates 100 Per Cent Efficacy Against Severe COVID-19, Overall Interim Clinical Efficacy 78 Per Cent by Swarajya Staff - Apr 21, 2021 10:42 AM Bharat Biotechâs COVAXIN Bharat Biotech and the Indian Council of Medical Research (ICMR) on Wednesday (21 April) announced phase 3 interim analysis results of India s first indigenous COVID-19 vaccine, Covaxin. In a statement, Hyderabad-based Bharat Biotech said that the second interim analysis is based on accruing more than 87 symptomatic cases of COVID-19. Due to the recent surge in cases, 127 symptomatic cases were recorded, resulting in a point estimate of vaccine efficacy of 78% (95%CI: 61-88) against mild, moderate, and severe COVID-19 disease, said the company.

Krishna ellaBalram bhargavaNational institute of virologyIndian council of medical researchResearch developmentDepartment of health researchBharat biotechIndian councilMedical researchHyderabad based bharat biotechNational instituteManaging directorSecretary departmentHealth researchDirector generalEmergency use authorization

Covaxin shows overall 78 pc interim efficacy, 100 pc efficacy against severe COVID-19 disease

Covaxin shows overall 78 pc interim efficacy, 100 pc efficacy against severe COVID-19 disease
aninews.in - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from aninews.in Daily Mail and Mail on Sunday newspapers.

Andhra pradeshKrishna ellaBalram bhargavaSuchitra ellaUnion health ministryNational institute of virologyGlobal public healthIndian council of medical researchBharat biotechIndian councilMedical researchEfficacy resultsHyderabad based bharat biotechNational instituteManaging directorDirector general

Covaxin shows 78% efficacy in Phase 3 interim analysis, says Bharat Biotech

Covaxin shows 78% efficacy in Phase 3 interim analysis, says Bharat Biotech
business-standard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from business-standard.com Daily Mail and Mail on Sunday newspapers.

Krishna ellaBalram bhargavaNational institute of virologyIndian council of medical researchResearch developmentBharat biotechEmergency use authorizationsHyderabad based bharat biotechNational instituteIndian councilManaging directorMedical researchDirector generalகிருஷ்ணா எல்லாபால்ராம் பார்கவாதேசிய நிறுவனம் ஆஃப் வைராலஜி